Nemucore was founded and funded by the NIH to understand chemotherapy resistance with the mission to develop methods to overcome resistance in patients suffering with rare, lethal cancers.
Over the weekend, I had a wonderful opportunity to speak with several highly regarded clinical oncologists at a Conquer Cancer Foundation event. There was a lot discussion about the promise of immuno-oncology and precision medicine. However, as the discussions evolved it became quite apparent that one of the big opportunities in cancer therapy is understanding chemotherapy resistance. With this understanding of resistance, create more effective treatment approaches and essentially placing chemotherapy resistance on a similar level of concern as we currently apply to chemotherapy sensitivity.
During my discussions, it became apparent that these influential oncologists wished that biopharmaceutical companies would spend more time identifying why patients become resistant to chemotherapy and how to circumvent it!
As one oncologist put it ".....chemotherapy resistance is a major challenge in cancer treatment today as most patients who die from cancer after they acquire resistance to multiple lines of traditional and targeted chemotherapies"
For everyone who has been following Nemucore this should be music to your ears. Why??
Nemucore's precision medicine program for Acute Myeloid Leukemia (AML) measures signals that make a cancer sensitive and resistant to NMI-900 - exactly what the doctor ordered!
At Nemucore we have always believed that we are on the cutting edge of the next wave of precision medicine innovation with our NMI-900 program but this weekends discussions clearly place us in at the leading edge.
Investors who want to be part of a company at the leading edge of a revolution in precision medicine have until 10/25/2018 to participate in our current offering.
We hope you will become part of our mission to help people battling AML and other blood cancers!
Wefunder supports three different federal laws that allow startups to raise money legally. To comply with the law, Wefunder Advisors LLC and Wefunder Portal LLC (both owned by Wefunder Inc) also list startups depending on the regulation used.
Legal May 16th 2016
Wefunder Portal LLC
for 338 startups
Wefunder Advisors LLC
for 105 startups
for 3 startups
Curious how well the companies have done? Or how many raised follow-on financing?
Some fine print: 1) These numbers include startups currently live on Wefunder if they pass their minimum target. 2) Some startups use two different laws at the same time (i.e., Regulation D and Regulation Crowdfunding).
Join 563,992 investors who funded 425 startups with over $154.5 million1
wefunder.com/updates/95280-perspective-cancer-therapy-resistance is managed by
Wefunder Portal LLC.
Wefunder Inc. runs wefunder.com and is the parent company of Wefunder Advisors LLC and Wefunder Portal LLC. Wefunder Advisors is an exempt reporting adviser that advises SPVs used in Reg D offerings. Wefunder Portal is a funding portal (CRD #283503) that operates sections of wefunder.com where some Regulation Crowdfunding offerings are made.
Wefunder, Inc. operates sections of wefunder.com where some Regulation D and A offerings are made. Wefunder, Inc. is not regulated as either a broker-dealer or funding portal and is not a member of FINRA.
You may also view our Privacy Notice.